{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.532","value":"-8.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week +4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.543","value":"-9.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Week +8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.040","value":"-9.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week +16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.738","value":"-9.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Week +24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.212","value":"-8.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Week +28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.302","value":"-8.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Week +40"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.392","value":"-7.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Week +52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.902","value":"-10.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Week 92"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.288","value":"-8.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.708","value":"-9.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Week 117"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.740","value":"-10.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Week 130"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.030","value":"-8.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Week 143"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.573","value":"-9.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.305","value":"-11.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Week 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.113","value":"-10.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Week 182"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.357","value":"-10.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week 195"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.360","value":"-9.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Week 208"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.986","value":"-10.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 221"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.404","value":"-8.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Week 234"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.979","value":"-9.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Week 247"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to the BAT arm, who crossed over and received at least one dose of ruxolitinib","id":"OG000","title":"Best Available Therapy (BAT)"}],"paramType":"MEAN","populationDescription":"Cross-over set consisted of all participants randomized to the BAT arm, who crossed over and received at least one dose of ruxolitinib.","reportingStatus":"POSTED","timeFrame":"Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over","title":"Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","type":"SECONDARY","unitOfMeasure":"Score on a scale"}